Polyclonal antibody preparation that depletes T cells for GVHD prophylaxis.
Polyclonal anti–human T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, reducing alloreactive T cells to prevent GVHD.
ATG contains antibodies that bind CD11a (LFA-1) on T cells; antibody-coated cells are lysed by complement and cleared via Fc-mediated ADCC/phagocytosis.
Polyclonal antibody preparation that depletes T cells for GVHD prophylaxis.
Polyclonal anti–human T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, reducing alloreactive T cells to prevent GVHD.
ATG antibodies bind CD18 (LFA-1 beta) on T cells and trigger complement-dependent lysis and Fc-mediated ADCC/phagocytosis, depleting those cells.
Rabbit polyclonal antilymphocyte globulin used for in vivo T-cell depletion to reduce graft-versus-host disease risk.
Rabbit polyclonal IgG against multiple human T‑cell surface antigens (e.g., CD2, CD3, CD4, CD8, HLA) that depletes T lymphocytes via complement-dependent cytotoxicity, Fc-mediated ADCC/phagocytosis, and apoptosis, producing in vivo T‑cell immunosuppression to reduce GVHD risk.
rATG contains antibodies that bind HLA class I (including HLA-C) on cell surfaces, triggering complement-dependent cytotoxicity and Fc-mediated ADCC/phagocytosis, leading to cell death.
Polyclonal antibody preparation that depletes T cells for GVHD prophylaxis.
Polyclonal anti–human T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, reducing alloreactive T cells to prevent GVHD.
ATG contains antibodies that bind CD45 on leukocytes (including T cells) and induce complement-dependent lysis and Fc-mediated ADCC/phagocytosis, depleting CD45-expressing cells.
Autologous patient-derived CD4+/CD8+ T cells (LMY-920) gene-modified via a non-viral transposon to express a BAFF-ligand chimeric antigen receptor targeting BAFF-R/BR3, TACI, and BCMA to eliminate malignant B cells; dosed at 1–8×10^6 CAR+ cells/kg following lymphodepletion.
Autologous CD4+/CD8+ T cells engineered via a non-viral transposon to express a BAFF-ligand chimeric antigen receptor that binds BAFF family receptors (BAFF-R/BR3, TACI, BCMA) on malignant B cells; antigen engagement activates the CAR T cells to proliferate, secrete cytotoxic mediators/cytokines, and kill the target B cells.
BAFF-ligand CAR-T cells bind BAFF-R on target B cells, become activated, form an immunologic synapse, and kill via perforin/granzyme (and Fas/FasL) cytotoxic pathways.